5 Best Dialysis and Kidney Disease Stocks to Buy

4. Humana Inc. (NYSE:HUM)

Number of Hedge Fund Holders In Q2 2023: 70

Market Capitalization: $65 Billion

With a market capitalization of $65 billion, Humana Inc. (NYSE:HUM) provides a renal disease management program for patients with late-stage chronic kidney disease and end-stage renal disease. Headquartered in Kentucky and founded in 1961, Humana Inc. (NYSE:HUM) only offers services in the US and ranks 4th in our list of the best dialysis and kidney disease stocks to buy. It recently signed an agreement with kidney care management company, Interwell Health, to enhance treatment plans for patients with chronic kidney disease as well as end-stage kidney disease. Humana Inc. (NYSE:HUM) posted EPS of $8.67 at the end of Q2.

After digging through 910 hedge funds for their June quarter of 2023 shareholdings, Insider Monkey found out that 70 had invested in Humana Inc. (NYSE:HUM). Rajiv Jain’s GQG Partners is the biggest investor among these because of its $1.3 billion stake.